Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

The former EastEnders actress, 41, revealed that she had surgery to remove both of her breasts, as well as her fallopian ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

Hollie Nelsen, who has taught at Sarasota School of Arts and Sciences for the past 13 years, was diagnosed with stage 3 ovarian cancer in February 2025. Nelsen is an avid runner, and she was picked to ...